GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

PBYI · Mar 31, 2026

PUMA BIOTECHNOLOGY, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-26-015633General Corporate
Debt relative to revenue9thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.debt_to_revenue

25.31% · OPTIONAL · VALID

Capex intensity0thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · VALID

Operating cash generation100thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

34.40% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-2.59% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure100thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

19.40% · OPTIONAL · VALID

Gross margin64thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.gross_margin

76.74% · CORE · VALID

Operating margin0thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.operating_margin

-8.54% · CORE · VALID

SBC intensity45thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.23% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building
Jun 30, 20230/5 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20255/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20256/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
9.93%
Current
25.31%
Delta
15.38%
Capex Intensity Decreased
Previous
0.03%
Current
0.00%
Delta
-0.03%
Cash Generation Increased
Previous
18.30%
Current
34.40%
Delta
16.10%
Growth Decreased
Previous
-0.91%
Current
-2.59%
Delta
-1.68%
Inventory Pressure Increased
Previous
2.41%
Current
19.40%
Delta
16.98%
Margin Increased
Previous
74.53%
Current
76.74%
Delta
2.21%
Profitability Decreased
Previous
16.33%
Current
-8.54%
Delta
-24.87%
Sbc Intensity Increased
Previous
3.04%
Current
4.23%
Delta
1.19%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Has State · PUMA BIOTECHNOLOGY, INC. →Transitioned To · PBYI Fundamental State →Transitioned To · PBYI BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · PBYI CAPEX_INTENSITY_DECREASED →Transitioned To · PBYI CASH_GENERATION_INCREASED →Transitioned To · PBYI GROWTH_DECREASED →Transitioned To · PBYI INVENTORY_PRESSURE_INCREASED →Transitioned To · PBYI MARGIN_INCREASED →Transitioned To · PBYI PROFITABILITY_DECREASED →Transitioned To · PBYI SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.